Drug Approval | March 09, 2026
Lupin receives two observations from USFDA for Ankleshwar facility
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets
The facility is expected to become operational by FY2028-29
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Subscribe To Our Newsletter & Stay Updated
